Compare · ADMS vs RVPH
ADMS vs RVPH
Side-by-side comparison of Adamas Pharmaceuticals, Inc. (ADMS) and Reviva Pharmaceuticals Holdings Inc. (RVPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ADMS focuses on Major Pharmaceuticals, while RVPH focuses on Biotechnology: Pharmaceutical Preparations.
- ADMS is the larger of the two at $373.6M, about 82.8x RVPH ($4.5M).
- RVPH has hit the wire 1 time in the past 4 weeks while ADMS has been quiet.
- RVPH has more recent analyst coverage (6 ratings vs 5 for ADMS).
- Company
- Adamas Pharmaceuticals, Inc.
- Reviva Pharmaceuticals Holdings Inc.
- Price
- $8.21+0.61%
- $0.36-55.68%
- Market cap
- $373.6M
- $4.5M
- 1M return
- -
- -58.40%
- 1Y return
- -
- -97.90%
- Industry
- Major Pharmaceuticals
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2020
- News (4w)
- 0
- 1
- Recent ratings
- 5
- 6
Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
Latest ADMS
- SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)
- SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.
- SEC Form 4: Bigham Michael closing all direct ownership in the company
- SEC Form 4: Mahoney David L closing all direct ownership in the company
- SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Mcfarlane Neil F. was granted 75,000 shares, closing all direct ownership in the company
- SEC Form 4: Ericson William W. closing all direct ownership in the company
- SEC Form 4: Shreedhar Vijay was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Papapetropoulos Spyridon closing all direct ownership in the company
Latest RVPH
- Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
- Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form 10-Q filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits